BridgeBio Pharma (BBIO) news
Recent news
KKR's BridgeBio share sale allocated nearly 60% to five firms
On February 12, 2021, BridgeBio Pharma (BBIO) executed a secondary public offering of 3,000,000 shares of its common stock, priced at $62.50 per share, with KKR Genetic Disorder L.P. serving as the selling stockholder. The offering included an option for underwriters to purchase up to 450,000…
AInvest Wire · Aug 14, 2026KKR is said to offer BridgeBio shares at up to 4% discount
BridgeBio Pharma, Inc. (Nasdaq: BBIO) recently announced a $1 billion preferred equity investment led by Sixth Street and HealthCare Royalty, a business of KKR & Co. Inc. (NYSE: KKR). As part of the transaction, HealthCare Royalty contributed $133.9 million at the initial conversion price of…
AInvest Wire · Aug 13, 2026KKR is said to offer BridgeBoi Pharma shares for $78-$80 each
BridgeBio Pharma, Inc. (Nasdaq: BBIO) recently announced a $1 billion preferred equity investment led by Sixth Street and HealthCare Royalty, a business of KKR, at an initial conversion price of $137.79 per share, significantly above the company’s 30-day volume-weighted average price. This…
AInvest Wire · Aug 13, 2026Bridgebio Pharma reports launch of secondary offering
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the pricing of a public offering of 8,620,690 shares of its common stock at $29.00 per share, with gross proceeds expected to reach approximately $250.0 million before underwriting discounts and expenses. The company also granted underwriters a 30-day…
AInvest Wire · Aug 13, 2026Truist Securities raises target price to $107 from $102 for BridgeBio Pharma, Inc.
Truist Securities has raised its price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $107 from $102, maintaining a positive outlook on the biopharmaceutical company. The adjustment reflects the firm’s confidence in BridgeBio’s recent performance and commercial progress. In Q4 2025, the company…
AInvest Wire · Aug 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.